Robotic Prostate Cancer Surgery Team
Mount Sinai Urology is transforming prostate cancer treatment and expanding the scope of knowledge about the causes of and solutions for the disease. Our medical scientists conduct pivotal research that informs our diagnosis and treatment of prostate conditions. We provide care that is advanced, comprehensive, and compassionate, for patients from all corners of the United States and beyond.
Mount Sinai Urology is under the leadership of Department Chair Ashutosh (Ash) K. Tewari, MD, considered to be among the top prostate cancer urologists in the world.
Dr. Tewari joined us in 2013 and was already recognized as one of the foremost leaders in robotic prostate surgery and prostate cancer research. He received the 2012 American Urological Association Gold Cystoscope Award for outstanding contributions to the field of urology and urologic oncology. He has performed more than 5,500 robotic prostatectomies, making him one of the most experienced robotic surgeons in the world.
Dr. Tewari pioneered robot-assisted prostate removal (prostatectomy) and developed the Advanced Robotic Technique; this approach eliminates the cancer and minimizes the treatment’s effects on bowel, urinary, and sexual functioning. In addition, Dr. Tewari has developed a completely athermal technique (no use of cautery or heat energy) during robotic prostatectomy, in order to minimize the damage to the nerves responsible for erectile function. He has also created an approach to total reconstruction that restores the support structures of the urinary mechanism after prostate removal, for faster continence recovery. Dr. Tawari has authored more than 250 peer-reviewed articles on prostate cancer and robotic surgery.
Dr. Ketan K. Badani, Director of Robotic Surgery, has performed nearly 5,000 robotic procedures, and has the largest combined experience of robotic prostate and kidney cancer surgery in the country. Dr. Badani has published extensively on robotic prostatectomy and surgical outcomes including urinary and sexual function. He is also one of the most preeminent practitioners of robotic prostate cancer surgery in the world.
Dr. Tewari and Dr. Badani lead an exceptional team that takes a holistic approach to care. We aim to treat the whole person, not just the disease. We bring together a dedicated, multidisciplinary group of nearly two dozen professionals, including an operating team that has been involved in thousands of cases; a highly skilled nursing staff; and post-operative team, internists, medical oncologists, genomics experts, and surgeons.
Our team also includes experts in sexual and urinary health, high-risk cancer management, and radiation therapists to augment or supplement surgery. In addition, we offer nutrition and other specialized counseling services. When appropriate, we consult with Mount Sinai experts in an even wider range of disciplines, most often cardiologists, diabetes experts, and neurologists.
We are dedicated to improving patient outcomes through translational research. Our clinical and research teams work collaboratively to apply the latest knowledge to patient diagnosis and treatment. We are exploring the role of genetics in prostate cancer, designing new magnetic resonance imaging techniques for diagnosis, and multiphoton microscopy therapy (another imaging approach) to identify small nerves during cancer treatment and minimize the possibility of leaving some residual cancer in the body after robotic surgery.
Mount Sinai receives major funding from the National Institutes of Health, the Prostate Cancer Foundation, and others. We work collaboratively with other leading institutions, including Cold Spring Harbor Laboratory, MIT, Harvard Medical School, Dana-Farber Cancer Institute, Cornell University, The Broad Institute, and Rockefeller University.